ADMA Biologics's 15min Chart Shows Bullish Trend with Bollinger Bands Expanding Upward

According to the 15-minute chart of ADMA Biologics, the Bollinger Bands are expanding upward, indicating a bullish trend driven by strong buying activity. The recent Bullish Marubozu candlestick pattern at 10/07/2025 13:15 further reinforces this sentiment, suggesting that buyers are in control and are likely to continue driving the market momentum upward.

Adma Biologics (ADMA) has been exhibiting strong bullish trends, as indicated by the expanding upward Bollinger Bands on its 15-minute chart. This expansion suggests a period of increased buying activity and volatility, signaling a potential upward movement in the stock price. Additionally, the recent appearance of a Bullish Marubozu candlestick pattern on October 7, 2025, at 13:15 further supports this bullish sentiment. The Marubozu pattern, characterized by a candlestick with no wicks, signifies strong buying pressure and suggests that buyers are in control, likely to continue driving the market momentum upward.

In the latest trading session, ADMA closed at $15.05, marking a +2.66% gain from the prior day. This performance outpaced the S&P 500's daily gain of 0.34%, the Dow's 0.09% increase, and the tech-heavy Nasdaq's 0.42% rise. Over the past month, ADMA's stock has dropped by 14.77%, underperforming the Medical sector's gain of 1.97% and the S&P 500's 3.54% increase. Despite this recent decline, analysts predict that ADMA will post an earnings per share (EPS) of $0.16 for the current quarter, representing a 6.67% growth compared to the same quarter last year. Additionally, the consensus estimate for revenue is $130.1 million, indicating an 8.56% increase from the previous year.

For the full year, the Zacks Consensus Estimates project earnings of $0.57 per share and a revenue of $506.7 million, demonstrating changes of +16.33% and +18.82%, respectively, from the preceding year. The company's valuation, as indicated by its Forward P/E ratio of 25.72, is higher than the industry average of 18.92. This valuation suggests that investors are paying a premium for ADMA's growth potential.

Investors should also monitor any recent modifications to analyst estimates for ADMA, as these revisions can provide insights into near-term business trends. The Zacks Rank, a proprietary model that incorporates estimate changes, currently ranks ADMA at #3 (Hold). The Medical - Biomedical and Genetics industry, of which ADMA is a part, has a Zacks Industry Rank of 80, placing it in the top 33% of all 250+ industries.

For the latest financial data and recommendations, visit [Zacks Investment Research](https://www.zacks.com).